Treatment results in bulky and advanced Hodgkin's disease.
| Group/Reference . | Patients/Treatment . | N . | FFS% . | OS% . | Time (Yr) . |
|---|---|---|---|---|---|
| * p <0.05 | |||||
| Abbreviations: FFS, failure-free survival; OS, overall survival; CALGB, Cancer and Leukemia Group B ; ECOG, Eastern Cooperative Oncology Group; Milan, Milan Tumor Group; NCI-C, National Cancer Institute of Canada; GHSG, German Hodgkin Study Group; pRT, recurrence after therapy; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; MOPP, nitrogen mustard, vincristine, procarbazine, prednisone; ABV, doxorubicin, bleomycin, vinblastine; RT, radiotherapy; COPP, cyclophosphamide, vincristine, procarbazine, prednisone; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; escBEACOPP, escalated BEACOPP | |||||
| Chemotherapy Only | |||||
| CALGB | IIIA2,IIIB, IV, after RT | 361 | 5 | ||
| ABVD | 61* | 76 | |||
| MOPP/ABVD | 65* | 75 | |||
| MOPP | 50* | 66 | |||
| ECOG | IIIA2,IIIB, IV, after RT | 691 | 8 | ||
| MOPP → ABVD | 54* | ||||
| MOPP/ABV | 64* | ||||
| CALGB | III, IV, after RT | 856 | 3 | ||
| ABVD | 65 | 87 | |||
| MOPP/ABV | 67 | 85 | |||
| Chemotherapy + Radiotherapy | |||||
| Milan | IB, IIAbulky,IIB, III, IV | 427 | 10 | ||
| MOPP/ABVD + RT | 67 | 74 | |||
| Hybrid + RT | 69 | 72 | |||
| NCI-C | IIIB, IV, after RT | 301 | 5 | ||
| MOPP/ABVD + RT | 67 | 83 | |||
| Hybrid + RT | 71 | 81 | |||
| GHSG | IIB-IIIArisk, IIIB, IV | 1180 | 3 | ||
| COPP/ABVD + RT | 70* | 86* | |||
| BEACOPP + RT | 79* | 91* | |||
| EscBEACOPP + RT | 89* | 92* | |||
| Group/Reference . | Patients/Treatment . | N . | FFS% . | OS% . | Time (Yr) . |
|---|---|---|---|---|---|
| * p <0.05 | |||||
| Abbreviations: FFS, failure-free survival; OS, overall survival; CALGB, Cancer and Leukemia Group B ; ECOG, Eastern Cooperative Oncology Group; Milan, Milan Tumor Group; NCI-C, National Cancer Institute of Canada; GHSG, German Hodgkin Study Group; pRT, recurrence after therapy; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; MOPP, nitrogen mustard, vincristine, procarbazine, prednisone; ABV, doxorubicin, bleomycin, vinblastine; RT, radiotherapy; COPP, cyclophosphamide, vincristine, procarbazine, prednisone; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; escBEACOPP, escalated BEACOPP | |||||
| Chemotherapy Only | |||||
| CALGB | IIIA2,IIIB, IV, after RT | 361 | 5 | ||
| ABVD | 61* | 76 | |||
| MOPP/ABVD | 65* | 75 | |||
| MOPP | 50* | 66 | |||
| ECOG | IIIA2,IIIB, IV, after RT | 691 | 8 | ||
| MOPP → ABVD | 54* | ||||
| MOPP/ABV | 64* | ||||
| CALGB | III, IV, after RT | 856 | 3 | ||
| ABVD | 65 | 87 | |||
| MOPP/ABV | 67 | 85 | |||
| Chemotherapy + Radiotherapy | |||||
| Milan | IB, IIAbulky,IIB, III, IV | 427 | 10 | ||
| MOPP/ABVD + RT | 67 | 74 | |||
| Hybrid + RT | 69 | 72 | |||
| NCI-C | IIIB, IV, after RT | 301 | 5 | ||
| MOPP/ABVD + RT | 67 | 83 | |||
| Hybrid + RT | 71 | 81 | |||
| GHSG | IIB-IIIArisk, IIIB, IV | 1180 | 3 | ||
| COPP/ABVD + RT | 70* | 86* | |||
| BEACOPP + RT | 79* | 91* | |||
| EscBEACOPP + RT | 89* | 92* | |||